Core Viewpoint - The company has approved a total of 1.814 billion yuan in joint liability guarantees for its subsidiaries over the next 12 months, indicating a strategic move to support its healthcare operations [1] Group 1: Guarantees and Financial Support - The company has agreed to provide joint liability guarantees amounting to 300 million yuan and 500 million yuan for its wholly-owned subsidiaries, Wafangdian Third Hospital and Lankao First Hospital, respectively [1] - The guarantee period for both contracts is set at three years, reflecting the company's commitment to its subsidiaries [1] - As of June 30, the actual guarantee balance for the subsidiaries stands at 702 million yuan, which constitutes 35.39% of the most recent audited net assets, indicating a significant level of financial backing [1] Group 2: Risk Management - The board of directors believes that the risks associated with these guarantees are controllable and will not harm the interests of the company and its shareholders [1]

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention measures lifted and is now able to resume his duties, with the company's operations reported to be normal [1][3]. Group 1: Chairman's Status - Lin Yanglin was previously detained by the Taiyuan Municipal Xiaodian District Supervisory Committee for investigation, but the company confirmed that the matter was unrelated to its operations [1][3]. - Following the lifting of the detention, Lin Yanglin is back to fulfilling his responsibilities as chairman, and the company’s production and operational status is reported as normal [3]. - The company had previously indicated that the investigation would not have a significant adverse impact on its operations [3]. Group 2: Financial Performance - In the first half of the year, New Mileage reported a revenue of 1.588 billion yuan, a year-on-year decrease of 20.63%, and a net profit attributable to shareholders of 7.4311 million yuan, down 88.25% year-on-year [5]. - The medical services segment generated 1.38 billion yuan in revenue, while the pharmaceutical segment brought in 210 million yuan [5]. - The gross margin for the medical segment was 26.34%, which increased by 1 percentage point year-on-year, despite a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies [5]. - The pharmaceutical segment's gross margin was 40.47%, down 4.69 percentage points, primarily due to a decrease in sales prices following centralized procurement of core products [5]. Group 3: Market Dynamics - New Mileage participated in a national centralized procurement initiative for traditional Chinese medicine, with its product series "Duyiwei" expected to be selected for procurement [6]. - The implementation of centralized procurement faced delays, leading to a significant drop in sales initially, but sales have recently rebounded as confidence in the market has improved [6].

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention lifted, allowing him to resume his duties as chairman of the company [1] Company Summary - On September 22, New Mileage (002219) announced that it received a notification from Lin Yanglin's family regarding the lifting of his detention by the Taiyuan Municipal Xiaodian District Supervisory Committee [1] - The company confirmed that Lin Yanglin is now able to perform his responsibilities as chairman, and the company's production and operational status remains normal [1] - Xu Minggui will no longer act on behalf of Lin Yanglin as chairman [1]

Core Points - The company Xinlicheng (002219) announced on September 22 that its chairman Lin Yanglin has had the detention measures lifted by the Taiyuan City Xiaodian District Supervisory Committee [2] - Following the lifting of the detention, Lin Yanglin is now able to perform his duties as chairman normally, and the company's production and operational status is reported to be normal [2] - The company also stated that Xu Minggui will no longer act as the interim chairman [2]

Core Viewpoint - The company announced that its chairman, Mr. Lin Yanglin, has been released from detention and is able to resume his duties, indicating a return to normal operations for the company [1] Group 1 - The company received a notification from Mr. Lin Yanglin's family regarding the release from detention by the Taiyuan Municipal Xiaodian District Supervisory Committee [1] - The supervisory committee has officially lifted the detention measures against Mr. Lin Yanglin as of September 21, 2025 [1] - Mr. He Minggui will no longer act as the interim chairman, as Mr. Lin Yanglin is now able to fulfill his responsibilities as chairman [1]

Core Viewpoint - The company announced that its chairman, Lin Yanglin, has been released from detention and is able to resume his duties, indicating a return to normal operations for the company [1] Company Updates - Lin Yanglin was previously under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has now issued a notice of release from detention [1] - Following the release, Lin Yanglin is expected to fulfill his responsibilities as chairman, and Xu Minggui will no longer act in this capacity [1] - The company's production and operational status is reported to be normal [1]

证券简称：新里程 证券代码：002219 公告编号：2025-049 新里程健康科技集团股份有限公司 关于重大事项的进展公告 特别提示： 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司 2025 年 9 月 21 日，公司收到林杨林先生家属的通知，其收到太原市小店区 监察委员会出具的《解除留置通知书》，太原市小店区监察委员会已解除对林杨 林先生的留置措施。目前，林杨林先生已能正常履行公司董事长的职责，公司生 产经营情况正常。许铭桂先生将不再代为履行公司董事长的职责。 公司指定信息披露媒体为《证券日报》《证券时报》《中国证券报》《上海证 券报》和巨潮资讯网，公司发布的信息均以在上述媒体刊登的公告为准。敬请广 大投资者注意投资风险。 特此公告。 新里程健康科技集团股份有限公司 董 事 会 二〇二五年九月二十二日 1 新里程健康科技集团股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日披露《关于重大事项的公告》（公告编号：2025-041），公司董事长林杨林先生 被太原市小店区监察委员会实施留置并立案调查。 ...

Company Overview - New Mile Health Technology Group Co., Ltd. is located in Chaoyang District, Beijing, and was established on September 30, 2001. The company was listed on March 6, 2008. Its main business involves the manufacturing of pharmaceuticals (including traditional Chinese medicine) and medical services [1][2]. Financial Performance - For the period from January to June 2025, New Mile reported a revenue of 1.588 billion yuan, a year-on-year decrease of 12.76%. The net profit attributable to the parent company was 7.4311 million yuan, down 87.64% year-on-year [2]. - Since its A-share listing, New Mile has distributed a total of 70.3476 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 18, New Mile's stock price decreased by 2.01%, trading at 2.44 yuan per share, with a total market capitalization of 8.265 billion yuan. The stock has seen a year-to-date decline of 7.58%, but has increased by 11.42% over the last five trading days [1]. - The stock's trading volume on September 18 was 365 million yuan, with a turnover rate of 4.50% [1]. Shareholder Information - As of August 20, the number of shareholders for New Mile reached 69,300, an increase of 3.21% from the previous period. The average number of circulating shares per person was 47,238, a decrease of 3.11% [2]. - As of June 30, 2025, Hu Long Securities Co., Ltd. was the ninth largest circulating shareholder, holding 60 million shares, unchanged from the previous period [3]. Business Segmentation - The company's revenue composition is primarily from medical services (86.79%), followed by pharmaceuticals and medical products (13.12%), with other sources contributing 0.09% [1].

Market Overview - On September 17, the medical services sector rose by 0.02% compared to the previous trading day, with Yinos leading the gains [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Top Gainers in Medical Services Sector - Yinos (688710) closed at 46.85, with an increase of 8.65% and a trading volume of 46,200 lots, amounting to a transaction value of 207 million [1] - New Mileage (002219) closed at 2.49, up 4.18%, with a trading volume of 2,568,500 lots and a transaction value of 638 million [1] - Prasis (301257) closed at 50.33, increasing by 3.52% with a trading volume of 50,700 lots, totaling 249 million [1] Top Losers in Medical Services Sector - Medisi (688202) closed at 76.00, down 5.41%, with a trading volume of 91,400 lots and a transaction value of 700 million [2] - Yaoshi Technology (300725) closed at 44.74, decreasing by 5.11%, with a trading volume of 262,900 lots and a transaction value of 1.18 billion [2] - Zhaoyan New Drug (603127) closed at 40.40, down 4.27%, with a trading volume of 444,300 lots and a transaction value of 1.806 billion [2] Fund Flow Analysis - On the same day, the medical services sector experienced a net outflow of 626 million from institutional investors, while retail investors saw a net inflow of 482 million [2] - The top stocks by net inflow from institutional investors included Yinos (688710) with a net inflow of 26.06 million, and New Mileage (002219) with 38.30 million [3] - Conversely, the top stocks with net outflow from institutional investors included Yao Ming Kande (603259) with a net outflow of 428 million [3]

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]